Malaria

Novartis Pledges to Fight Tropical Diseases and Malaria

Swiss drugmaker Novartis has made a five-year financial commitment of $250 million to fight neglected tropical diseases (NTDs) and malaria.

News

BioNTech Developing new Malaria Vaccine

BioNTech has launched a new project aimed at developing what it hopes will be a well-tolerated and highly effective malaria vaccine for the African continent. The Mainz, Germany-based company, which developed a Covid-19 vaccine together with Pfizer in only ten months, said its goal is to produce the malaria vaccine locally.

Top-Feature

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

INOSIM GmbH

Predictive Simulation in Pharma Production

From Catalogue to Collaboration

Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Novartis Pharma GmbH